VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study is a local, prospective, open-label, company-sponsored, non interventional,
multi-center study. Patients documented must suffer from an acute exacerbation of chronic
bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to
obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of
acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely
prescribed. The secondary objective is to find out the possible correlation between the risk
factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different
treatment effectiveness according to Anthonisen classification. This study will also collect
the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection
in treating Acute Exacerbations of Chronic Bronchitis (AECB).
Details
Lead Sponsor:
Bayer
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination